Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL267534 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL1232002 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL3185849 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL996469 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL3181704 | 1.00 | MEN1 (0.52) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL6578082 | 0.92 | MEN1 (0.44) | MEN1KMT2ATSHRALDH1A1USP2 | |
| SCHEMBL4140372 | 0.87 | USP2 (0.63) | TSHRALDH1A1USP2KDM4ELMNA | |
| SCHEMBL4154180 | 0.87 | USP2 (0.63) | TSHRALDH1A1USP2KDM4ELMNA | |
| SCHEMBL4149480 | 0.87 | USP2 (0.63) | TSHRALDH1A1USP2KDM4ELMNA | |
| SCHEMBL4148516 | 0.87 | USP2 (0.63) | TSHRALDH1A1USP2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815790-B2 | Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-14 | — | — | US | disclosed |
| US-20170057922-A1 | CHEMICALLY MODIFIED QUINOLINE AND QUINOLONE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057922-A1 | CHEMICALLY MODIFIED QUINOLINE AND QUINOLONE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, CNR2, OPRK1 | MEN1 2202/4885KMT2A 1959/4885TSHR 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.